
Motif Neurotech became the first investment of One Giant Leap Ventures, Rice University's new venture fund offering up to $500,000 per investment. The Rice spinout is developing a minimally invasive brain implant for treatment-resistant depression.
Motif Neurotech activated the first site of its RESONATE study, opening enrollment at the University of Iowa. The early feasibility trial tests the DOT, a blueberry-sized wirelessly powered implant that sits in the skull above the brain without touching it, delivering stimulation to a region linked to depression. The study will expand to eight sites across six cities, evaluating safety over 12 months in patients with treatment-resistant depression. Motif positions the device as a durable alternative to repeated TMS sessions.